Quarterly ResultMay 12, 2026, 04:13 PM
Bolt Biotherapeutics Q1 Revenue Plunges 98%; Raises Going Concern Doubt
AI Summary
Bolt Biotherapeutics reported a significant decline in Q1 2026 collaboration revenue to $26,000, a 98% drop year-over-year. Despite this, the company's net loss improved to $7.2 million from $11.0 million in Q1 2025, driven by reduced operating expenses. However, management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash and marketable securities to fund operations for at least one year.
Key Highlights
- Management raised substantial doubt about Bolt Biotherapeutics' ability to continue as a going concern.
- Collaboration revenue for Q1 2026 plummeted 98% to $26,000 from $1.22 million in Q1 2025.
- Net loss for Q1 2026 improved to $7.24 million, down from $11.04 million in Q1 2025.
- Net loss per share improved to $(4.31) in Q1 2026 from $(5.76) in Q1 2025.
- Research and development expenses decreased 49% to $4.83 million in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $23.9 million as of March 31, 2026.
- Net cash used in operating activities decreased 40% to $8.02 million in Q1 2026.
- Total assets decreased to $48.03 million as of March 31, 2026, from $56.75 million at year-end 2025.